Acrivon Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Acrivon Therapeutics's estimated annual revenue is currently $12.1M per year.
- Acrivon Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Acrivon Therapeutics has 78 Employees.
- Acrivon Therapeutics grew their employee count by 37% last year.
Acrivon Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | VP Quality and Compliance | Reveal Email/Phone |
3 | VP Finance and Accounting | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | VP, Biology & Drug Discovery | Reveal Email/Phone |
6 | VP, Head Human Resources | Reveal Email/Phone |
7 | SVP, Head Clinical Operations | Reveal Email/Phone |
8 | VP, Head Data Science | Reveal Email/Phone |
9 | SVP and Head, Investor Relations and Corporate Affairs | Reveal Email/Phone |
10 | SVP, Global Regulatory Affairs | Reveal Email/Phone |
Acrivon Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Acrivon Therapeutics?
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.
keywords:N/AN/A
Total Funding
78
Number of Employees
$12.1M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15.7M | 78 | -38% | $156M |
#2 | $11.3M | 78 | 56% | N/A |
#3 | $12.1M | 78 | 5% | N/A |
#4 | $22.6M | 78 | 7% | N/A |
#5 | $8M | 78 | 3% | N/A |